Sun Pharma To Test Drug In Covid Cases

Mail Today|May 30, 2020

We're offering this story for free to read so that you can stay updated on the COVID-19 outbreak
Sun Pharma To Test Drug In Covid Cases
It has already started making the medicine to reduce delivery time

Indian pharma giant Sun Pharmaceutical Industries Ltd announced on Friday that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in COVID-19 patients. Nafamostat is approved in Japan for the improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

The approval came after a group of scientists from the University of Tokyo, Japan, and Leibniz Institute for Primate Research, Germany, recently demonstrated that Nafamostat, at very low concentrations, suppresses a protein that COVID-19 virus uses to enter human lung cells.

The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine.

articleRead

You can read up to 3 premium stories before you subscribe to Magzter GOLD

Log in, if you are already a subscriber

GoldLogo

Get unlimited access to thousands of curated premium stories and 5,000+ magazines

READ THE ENTIRE ISSUE

May 30, 2020